Prime Medicine

Historical price data

Prime Medicine's mission is to deliver on the promise of Prime Editing, a next-generation gene editing technology designed to correct the vast majority of disease-causing mutations with high precision and safety. The company has advanced from foundational research into the clinic, with initial programs for chronic granulomatous disease (CGD) and other indications now generating early human data. Its strategy leverages a single, versatile platform to build a broad pipeline of one-time therapies, aiming to transform treatment paradigms across genetic medicine.

Prime Editing is a next-generation gene editing platform that functions as a 'DNA word processor' to precisely search for and replace faulty genetic sequences without causing double-strand DNA breaks, aiming to correct the vast majority of known disease-causing mutations.

Prime Medicine competes with first-generation CRISPR companies (CRISPR Therapeutics, Intellia, Editas), base editing leader Beam Therapeutics, and large pharma with gene therapy ambitions. Its differentiation lies in its foundational Prime Editing IP and the technology's potential for greater versatility and precision, though clinical data will be the ultimate arbiter.